Geode Capital Slowly Builds Position in PDSB Stock

According to a recent Form 13F filing submitted to the SEC, Geode Capital Management, LLC disclosed a noteworthy and bullish investment in PDSB stock. Here’s what you need to know about PDS Biotechnology Corporation, as well as Geode Capital Management and their long position in shares of PDSB stock:

About Geode Capital Management

Boston, Massachusetts-based Geode Capital Management is a systematic asset manager providing core beta exposures across a range of equity and niche asset classes. Geode was founded in 2001 and set out to create structured and repeatable investment strategies with the objective of providing efficient exposures to institutional investors.

About PDS Biotechnology Corporation (PDSB)

PDS Biotechnology Corp., a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. PDSB is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Geode Capital Management Buys Stock in PDSB

According to the most recent 13F filed by Geode Capital Management, Llc, the firm added 25,665 shares of PDSB stock to it holdings in the recent quarter. That brings their total long position in PDS Biotechnology Corporation to 270,455 shares, representing approximately 0.9503% of the 28,458,701 PDSB shares outstanding. Based on the most recent closing price of $5.60 per share of PDSB, the entire Geode Capital Management, Llc position in PDS Biotechnology Corporation is worth roughly $1,514,548.00.

Summary

Be sure to check out more recent 13F filings here to stay up to date on the latest disclosures from institutional investment managers like Geode Capital Management. Also be sure to check out more recent 13F filing analysis news here.